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AbstrACt
Introduction Recent studies demonstrate that 
cardiovascular diseases and associated complications 
are the leading cause of morbidity and mortality in 
individuals with spinal cord injury (SCI). Abnormal arterial 
stiffness, defined by a carotid–to-femoral pulse wave 
velocity (cfPWV) ≥10 m/s, is a recognised risk factor for 
heart disease in individuals with SCI. There is a paucity 
of studies assessing the efficacy of conventional training 
modalities on arterial stiffness and other cardiovascular 
outcomes in this population. Therefore, this study aims 
to compare the efficacy of arm cycle ergometry training 
(ACET) and body weight-supported treadmill training 
(BWSTT) on reducing arterial stiffness in individuals 
with chronic motor complete, high-level (above the sixth 
thoracic segment) SCI.
Methods and analysis This is a multicentre, randomised, 
controlled, clinical trial. Eligible participants will be 
randomly assigned (1:1) into either ACET or BWSTT 
groups. Sixty participants with chronic (>1 year) SCI will be 
recruited from three sites in Canada (Vancouver, Toronto 
and Hamilton). Participants in each group will exercise 
three times per week up to 30 min and 60 min for ACET 
and BWSTT, respectively, over the period of 6 months. 
The primary outcome measure will be change in arterial 
stiffness (cfPWV) from baseline. Secondary outcome 
measures will include comprehensive assessments of: 
(1) cardiovascular parameters, (2) autonomic function, (3) 
body composition, (4) blood haematological and metabolic 
profiles, (5) cardiorespiratory fitness and (6) quality of life 
(QOL) and physical activity outcomes. Outcome measures 
will be assessed at baseline, 3 months, 6 months and 
12 months (only QOL and physical activity outcomes). 
Statistical analyses will apply linear-mixed modelling to 
determine the training (time), group (ACET vs BWSTT) and 
interaction (time × group) effects on all outcomes.
Ethics and dissemination Ethical approval was obtained 
from all three participating sites. Primary and secondary 
outcome data will be submitted for publication in peer-
reviewed journals and widely disseminated.
strengths and limitations of this study
 ► Cardiovascular Health/Outcomes: Improvements 
Created by Exercise and education in SCI (CHOICES) 
is the first trial to compare the effectiveness of 
two conventional exercise modalities: (1) active 
upper-body arm  cycle ergometry training and (2) 
passive lower  extremity body weight-support-
ed treadmill training across a plethora of health 
outcomes.
 ► Unlike other interventions in this population, par-
ticipants are somewhat homogeneous {ie, cervical 
and high thoracic motor complete spinal cord injury 
(SCI)}.
 ► The diversity of cardiovascular outcomes collected 
in the CHOICES trial is unique, including assess-
ments of both novel and traditional cardiovascular 
risk factors.
 ► The techniques employed to measure various out-
comes in this study have been shown to be valid and 
reliable, specifically in individuals with SCI.
 ► Limitations of this trial are: the lack of a follow-up 
time point for physiological outcomes to ascertain 
whether favourable adaptations persist beyond the 
intervention period and lack of blinding (masking) of 
outcome assessors to intervention allocation.
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trial registration number NCT01718977; Pre-results.
trial status Recruitment for this study began on January 2013 and the 
first participant was randomized on April 2013. Recruitment stopped on 
October 2018.
bACkground 
Inactivity related chronic diseases, such as cardiovas-
cular disease (CVD) and type 2 diabetes mellitus, occur 
at a heightened frequency and earlier in the lifespan in 
individuals with spinal cord injury (SCI) compared with 
able-bodied individuals.1 2 Individuals with high-level, 
motor complete SCI appear to be at greatest risk of devel-
oping cardiometabolic disease.3 4 The reasons for this 
are multifactorial. Not only are these individuals more 
sedentary5 but injuries sustained at or above the sixth 
thoracic level (≥T6) can disrupt autonomic pathways (ie, 
neural control over cardiac muscle, smooth muscle and 
glands),6 7 which consequently perturbs cardiovascular 
homeostasis. Such injuries can therefore impair cardio-
vascular responses to exercise,8 alter circadian oscillations 
in blood pressure (BP)9 10 and produce autonomic dysre-
flexia (AD),11 which is an acute episodic bout of hyper-
tension. It has been suggested that such instabilities in 
BP could contribute to vascular injury and consequently 
result in a greater risk for arterial disease in individuals 
with SCI.12 
Beyond the pathological concerns of BP lability, immo-
bilisation postinjury can lead to rapid changes in arterial 
structure and function as the cardiovascular system adapts 
to revised metabolic demands. Remodelling of peripheral 
arteries in the paralysed lower extremities (ie, reductions 
in diameter and flow in the femoral artery) occur within as 
little as 6 weeks postinjury.13 While systemic remodelling 
of the resistance arteries likely takes longer, aortic pulse 
wave velocity (aPWV), which is a measure of central artery 
stiffness, has been shown to be significantly elevated in 
men with SCI compared with age-matched, sex-matched, 
height-matched and weight-matched controls.14 This is 
of clinical relevance given aPWV has been directly linked 
with cardiovascular mortality, fatal and nonfatal coronary 
events and fatal stroke in able-bodied individuals.15 16 
Moreover, aPWV has been shown to have cardiovascular 
prognostic value above and beyond that of traditional 
risk factors, such as age, sex, BP, cholesterol, diabetes and 
smoking.17 18 Pulse wave velocity is largely determined by 
the elastic properties of the artery19 and is measured as 
the velocity of the arterial BP wave as it travels a known 
distance between two anatomical sites, commonly the 
carotid and femoral arteries. Although aPWV is still 
commonly used in the literature, a more accurate termi-
nology is carotid-to-femoral pulse wave velocity (cfPWV), 
which shall be used from here forward. Sympathetic tone 
changes in individuals with high-level SCI are important 
to consider when measuring the peripheral vasculature. 
However, the measure of cfPWV is specifically a measure 
of central conduit artery stiffness, not peripheral muscular 
artery stiffness. Therefore, we contend that conduit artery 
stiffness is more likely a result of structural changes in 
collagen and elastin deposition in the artery itself (thus 
representative of atherosclerotic vascular disease), rather 
than changes in the sympathetic tone of the artery per se.
Exercise interventions to improve cardiovascular health in 
individuals with chronic sCI
Given the prevalence of inactivity in individuals with SCI5 
and the well-accepted evidence in able-bodied individuals 
that physical activity confers multiple beneficial effects,20–22 
it is logical to hypothesise that increasing physical activity 
through exercise may reduce CVD risk in individuals with 
SCI. However, a recent 16-week randomised controlled 
trial, whereby participants performed ≥40 min/week 
moderate-to-vigorous upper body exercise and resistance 
training, showed no improvement in CVD risk factors (ie, 
arterial stiffness, endothelial function, body composition 
parameters and metabolic profile).23 Moreover, cross-sec-
tional data suggest that objectively measured physical 
activity is not associated with biomarkers of cardiometa-
bolic disease risk in individuals with paraplegia.24 Given 
these findings, the small sample sizes and considerable 
variability in the existing exercise training literature 
in individuals with SCI with regards to (1) the exercise 
intervention tested (ie, exercise modality, frequency, 
duration, intensity), (2) participant demographics, (3) 
research design and (4) outcome measures collected, it is 
currently challenging to provide evidence-based exercise 
prescriptions.
Two popular training modalities employed in the SCI 
community are arm cycle ergometry training (ACET) 
and body weight-supported treadmill training (BWSTT). 
Given the loss of motor function in the lower limbs, 
upper extremity exercise via ACET is a common and 
practical choice for increasing physical activity in indi-
viduals with SCI in community settings. While improve-
ments in cardiorespiratory fitness, power output and 
certain cardiometabolic risk factors (ie, insulin sensitivity 
and inflammatory cytokines) have been observed with 
moderate-intensity ACET in individuals with SCI,25–27 
little is known regarding its impact on arterial stiffness 
and endothelial function. In terms of upper body aerobic 
exercise, it is notable that blood flow to the lower limbs 
does not change during arm crank exercise in individuals 
with SCI,28 which may limit ACET-induced improvements 
in autonomic function and vascular adaptations at the 
systemic level. Thus, ACET may not provide the neces-
sary physical (BP and flow) and metabolic stresses to alter 
vascular function below the level of the lesion among 
individuals with motor complete SCI.
BWSTT has predominantly been used as a rehabil-
itation intervention to stimulate plasticity within the 
spinal cord29 and to promote the recovery of walking in 
individuals with motor incomplete SCI.30 31 Neverthe-
less, emerging data indicate that BWSTT also improves 
blood lipid profile, glucose tolerance, insulin sensitivity, 
body composition and autonomic regulation of cardio-
vascular function.32–34 In experimental rodent models of 
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SCI, passive hind-limb cycling also improves cardiac func-
tion35 and reduces the severity of AD.36 Although walking 
is passive, locomotion is usually initiated by robotic assis-
tance, manually by physical therapists, or transcutaneous 
electrical stimulation,37 the cyclical movements of the 
large muscles in the legs combined with the upright 
posture provide a considerable challenge to the cardio-
vascular system, potentially promoting positive training 
adaptations. For these reasons, it is believed BWSTT may 
provide a more superior exercise modality for individuals 
with motor complete SCI.
trial objectives
To determine whether BWSTT has beneficial effects, 
over and above ACET, on arterial stiffness (measured 
via cfPWV) and secondary health outcomes: (1) cardio-
vascular parameters, (2) autonomic function, (3) body 
composition, (4) blood haematological and metabolic 
profile, (5) cardiorespiratory fitness and (6) quality of 
life and physical activity outcomes in individuals with 
chronic (≥1 year postinjury), motor complete, cervical 
and high-thoracic SCI. In comparison with ACET, we 
hypothesise that, through large muscle mass involve-
ment and postural challenge, the physical and metabolic 
stimuli of BWSTT will reduce cfPWV by 1 m/s in individ-
uals with established risk (ie, cfPWV ≥ norm median value 
of age-matched able-bodied individuals at baseline).38 
Changes >1 m/s likely represent true changes in health 
status in individuals with SCI.39
MEthods And AnAlysIs
study design and setting
The Cardiovascular Health/Outcomes: Improvements 
Created by Exercise and education in SCI (CHOICES) 
study is a prospective, multicentre, randomised controlled 
clinical trial. An overview of the planned experimental 
design is illustrated in figure 1. The trial will involve an 
initial or baseline assessment period, followed by assess-
ments at 3 months and 6 months of exercise training 
and a 6-month follow-up assessment (12 months), for 
quality of life and physical activity outcomes. All testing 
and exercise training will take place at three Canadian 
sites: (1) International Collaboration On Repair Discov-
eries (ICORD) at the University of British Columbia in 
Vancouver, (2) McMaster University in Hamilton, and (3) 
the Lyndhurst Centre, Toronto Rehabilitation Institute – 
University Health Network in Toronto.
recruitment
Participants (n=60) will be recruited from the three 
aforementioned study sites (n=~20 at each site). Poten-
tial participants will be identified through a variety of 
recruitment strategies including: (1) posters, which 
will be distributed among hospital locations and local 
community venues (excluding local sports venues and 
community programme centres), (2) social media adver-
tising (ie, websites, Facebook and Twitter), (3) a letter 
of introduction outlining the purpose of the study and 
(4) at the individual’s request. Inclusion and exclusion 
criteria are outlined in table 1.
randomisation
Eligible individuals will be randomly assigned (1:1) to 
either treatment ACET or BWSTT. Groups will be strat-
ified by injury level (cervical and thoracic) and age (≤30 
years and >30 years). Allocation will be concealed using 
a central, web-based computer randomisation service 
(Empower: http://www. empo werh ealt hres earch. ca/). 
A statistician independent of the trial will generate the 
randomisation sequence; permuted blocks of varying size 
will be employed.
Patient and public involvement (PPI)
Patients and community-dwelling individuals with SCI 
were not formally involved in the development of the 
trial (ie, formulating the research questions, design of the 
study or the selection of outcome measures) from a clas-
sical PPI perspective. However, we would like to empha-
sise that the majority of individuals with SCI consider 
exercise important for functional recovery.40 Informal 
conversations and feedback from individuals with SCI was 
taken into consideration. A number of the study team 
were and still are actively engaged with the wider SCI 
community and pertinent information was incorporated 
into this study protocol.
Exercise interventions
The exercise interventions will be implemented three 
times per week, with the aim for participants to complete 
continuous exercise, 30 min per session for ACET and 
60 min per session for BWSTT, over a period of approx-
imately 24 weeks (n=72 exercise sessions). During the 
trial, participants will be asked not to alter their physical 
activity, diet or medications. Should a change in life-
style behaviours occur, participants will be encouraged 
to report to the study coordinators to document these 
changes and assess their impact on trial eligibility. Partic-
ipants are expected to attend at least 75% of the planned 
exercise training sessions (n>54). Adherence will be peri-
odically assessed at 8 weeks and 16 weeks to determine 
feasibility of intervention completion for each partic-
ipant. Given the real-world nature of this trial, and the 
associated complexities of working with this population 
(ie, frequent medical appointments or complications and 
transportation issues), there will be an opportunity for 
participants to compensate for missed exercise sessions 
as described in figure 2. Participants unable to comply 
with the adherence criterion will be asked to withdraw 
from the trial. Prior to randomisation, all participants 
will be asked to perform a familiarisation training session 
to establish their baseline exercise capacity [ie, tolerable 
weight support/speed, height of the ergometer, rate of 
perceiving exertion (RPE) and heart rate (HR)].
RPE will be recorded between bouts and at the end 
of each training session using the Borg scale. For safety 
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reasons, stop criteria for individual exercise sessions for 
each intervention will be set at a rating of 14 on the 6–20 
Borg scale,41 a systolic BP change ±30 mm Hg from resting 
condition, a HR <50 bpm or >150 or symptoms of AD (ie, 
pounding headache, heart palpitations and upper body 
flushing/sweating) or orthostatic hypotension (OH) 
(ie, light-headedness, dizziness and changes in vision). 
With these conditions, participants will rest for 5 min and 
will be asked if they want to stop or resume the exercise 
session.
Example exercise intensity progressions for both 
exercise interventions are outlined in table 2. These 
progressions are only suggestions for resistance (ACET) 
and speed (BWSTT). ACET prescribed at 3×30 min per 
week is in accordance with the updated SCI-specific 
exercise guidelines to achieve cardiometabolic health 
benefits42 and should reduce the risk of an overuse injury. 
Currently, no guidelines exist for the most appropriate 
volume of BWSTT in persons with motor complete SCI; 
the 60 min duration was chosen based on prior BWSTT 
interventions.33 43 Furthermore, due to the passive nature 
of BWSTT, we anticipated that participants in this inter-
vention arm will experience lower exercise session RPEs. 
Therefore, BWSTT exercise sessions will be longer in 
duration to approximate the training load between the 
two groups.
Arm cycle ergometry training
ACET will be performed on a wall-mounted arm cycle 
ergometer (Lode BV, Groningen, The Netherlands; 
Vancouver site, Monark 881E, Monark Exercise AB, 
Vansbro, Sweden; Toronto and Hamilton sites) against 
Figure 1 Trial flow chart. ACET, arm cycle ergometry training; BWSTT, body weight-supported treadmill training.
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individually determined levels of resistance figure 3A. 
This protocol can be successfully implemented in indi-
viduals with upper cervical SCI by using tensor bandages 
to secure the participants’ hands to the ergometer.44 The 
height of the ergometer will also be electronically posi-
tioned so that the crank apex will be at or lower than the 
height of the participants’ shoulders. Participants will be 
asked to keep the cadence >50 revolutions per minute 
(rpm). During the initial stages of training, participants 
will have 5 min rest periods between bouts as outlined in 
table 2.
body weight-supported treadmill training protocol
The protocol for BWSTT used in this trial is based on 
the experience of the investigative team and prior publi-
cations.43 45 The locomotor training protocol will consist 
of training individuals on a treadmill (Woodway, Weil am 
Rhein, Germany; Vancouver and Hamilton sites, Thera-
Stride, Innoventor St Louis, Missouri, USA; Toronto site) 
using a body weight-support system (Andago, Hocoma 
AG, Volketswil, Switzerland). A minimum of two trainers 
will perform BWSTT figure 3B. At the Vancouver site, 
students from the Kinesiology School at the University 
of British Columbia will assist with the training after 
receiving appropriate guidance from physiotherapists 
with BWSTT experience. Skin checks will be performed 
prior to and after each training session to ensure the 
participant is not experiencing shear or developing tissue 
injury from the harness. Where appropriate, adjustments 
to the harness will be provided. During the initial stages 
of training, participants will be allowed to have 5 min rest 
periods between BWSTT bouts as described in table 2, 
where they will be lowered into a seated position to avoid 
syncope between walking intervals.
Assessments
Following screening and the provision of informed 
consent, participants will be enrolled into the trial. 
The collection of primary (baseline, 3 months and 
6 months) and secondary (baseline, 6 months and 
12 months) outcome measures (table 3) will be 
performed by an assessor who is unblinded to the 
participants’ group allocation. This trial is consistent 
with the Standard Protocol Items: Recommenda-
tions for Interventional Trials guidelines.46 To ensure 
fidelity of assessments, the principal investigators (PIs) 
and personnel from all sites had an initial face-to-face 
meeting where standardised training was performed. 
Common standardised operating procedures will be 
adhered to across all sites and regular 6-month video 
conferences will be arranged to serve as refreshers for 
study personnel. Moreover, the executive committee 
(consisting of trial PIs and research coordinators) will 
convene regularly to discuss any data collection issues 
that might arise.
Primary outcome measure: arterial stiffness
Following a 4-hour fast, cfPWV will be measured in 
the supine position following 10 min of rest. Arterial 
pressure waveforms will be collected at the carotid 
and femoral arterial sites for a minimum of 30 s using 
applanation tonometry47 (model SPT-301; Millar Instru-
ments, Houston, Texas, USA). Waveforms will be band-
pass filtered (2–30 Hz) and the arrival of waveforms at 
each site will be identified as the minimum value of the 
filtered signal. cfPWV will be calculated by dividing 80% 
of the distance between measurement sites by the pulse 
transit time collected over 10 s. Pulse transit time will 
be determined as the time delay between the arrival of 
Table 1 Participant inclusion and exclusion criteria
Inclusion criteria
1. Adults 18–60 years of age.
2. Sustained a motor complete (AIS, A or B) traumatic SCI 
between the fourth cervical (C4) and sixth thoracic (T6) 
level ≥1 year prior.
3. Competent to provide informed consent.
4. Able to commit to three 60 min exercise sessions per week 
for 24 weeks.
5. A cfPWV ≥ norm median value of age-matched able-bodied 
individuals38
a. < 30 years=6.1 m/s.
b. 30–39 years=6.4 m/s.
c. 40–49 years=6.9 m/s.
d. 50–59 years=8.1 m/s.
e. ≥60 years=9.7 m/s.
Exclusion criteria
1. History and/or symptoms of CVD or cardiopulmonary 
problems/disease.
2. Major trauma or surgery within the last 6 months.
3. Active stage 3 or 4 pressure ulcer (based on the National 
Pressure Ulcer Advisory Panel classification).
4. Recent (within 1 year) history of lower extremity fracture or 
non-union fracture.
5. Any unstable medical/psychiatric condition or substance 
abuse disorder that is likely to affect their ability to complete 
this study.
6. Individuals with active medical issues such as urinary tract 
infections, hypertension or heart disorders.
7. Any cognitive dysfunction or language barrier that would 
preclude participants from following English instructions.
8. Weighing >135 kg (absolute weight capacity of the body 
weight-supported treadmill).
9. Participants may be excluded at the discretion of the 
principal investigator due to unforeseen behavioural or safety 
issues.
AIS, American Spinal Injury Association Impairment scale; cfPWV, carotid-femoral pulse wave velocity; CVD, cardiovascular disease; SCI, 
spinal cord injury.
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the waveform at the carotid and femoral sites. Distance 
between the sites will be measured along the surface of 
the body using anthropometric measuring tape held 
parallel to the testing table. The mean of two 10 s collec-
tions will be analysed, and if their difference is >0.5 m/s, 
a third 10 s section will be analysed and the median of the 
three values will be reported. HR will be determined from 
concurrent single-lead electrocardiography (model ML 
123, ADInstruments, Colorado Springs, Colorado, USA), 
while BP will be measured in triplicate (the mean will 
be used for analysis) from the left arm following data 
collection (Dinamap Carescape V100; GE Healthcare, 
Buckinghamshire, UK). We have previously demon-
strated acceptable inter-rater and intra-rater reliability of 
this assessment for persons with SCI in our laboratory.47
secondary outcome measures
Cardiovascular parameters
Left ventricular structure and function (Vancouver site only)
Parasternal and apical views of the left ventricle will be 
collected using two-dimensional echocardiography (Vivid 
7, GE Healthcare, Horton, Norway) and analysed offline 
Figure 2 Adherence infographic.
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using a dedicated software system (EchoPAC; GE Health-
care, Horton, Norway) according to the recommenda-
tions of the American Society for Echocardiography.48–50 
All indices will be determined from the average of 
three cardiac cycles and will include measures of left 
ventricle structure, global systolic and diastolic function, 
and mechanics. The research team have considerable 
expertise with assessing these indices in persons with 
SCI.51 52 Echocardiography will only be performed at the 
Vancouver site.
Orthostatic intolerance: sit-up test
The presence or absence of OH will be determined using 
a sit-up test, which we have previously shown to be a reli-
able assessment in individuals with SCI.53 Prior to testing, 
participants will be instructed to empty their bladder to 
minimise the risk of reflex sympathetic activation. Partici-
pants will be secured to a specialised table (Sonesta Linak; 
Solna; Sweden) (except at the Hamilton site where investi-
gators will passively sit participants up) and passively moved 
to an upright position for 15 min, following 10 min of supine 
rest. Participants will be instructed not to assist with the 
manoeuvre and the test will be terminated early should they 
experience severe symptoms of presyncope. HR and BP 
will be measured continuously via single-lead ECG (Model 
ML132; ADInstruments, Colorado Springs, Colorado, USA) 
and by a non-invasive BP machine that places a cuff on the 
right middle finger (Finometer PRO; Finapres Medical 
Systems, Amsterdam, The Netherlands), respectively. BP 
will also be measured at 1 min intervals using an automated 
device (Dinamap Carescape V100; GE Healthcare, Buck-
inghamshire, UK) with a cuff placed on the left upper arm. 
OH will be defined as a decline in systolic BP ≥20 mm Hg or 
diastolic BP ≥10 mm Hg when upright.54
BP lability: 24-hour BP monitoring
The monitoring of 24 hour BP is based on the previous 
experience of the study team.55 Continuous BP monitoring 
Table 2 Example progression of arm cycle ergometery training (ACET) and body weight-supported treadmill training (BWSTT)
ACET
Week
Resistance
(W) Cycling rate (rpm)
Bout duration
(min) Bouts
Total duration
(min)
1 0 50 5 3 15
2 5 50 5 4 20
3 10 50 5 5 25
4 10 50 5 6 30
5 10 50 10 3 30
6 15 50 15 2 30
7 15 50 30 1 30
8 15 50 30 1 30
BWSTT
Week
Body-weight support
(%)
Speed
(km/hour)
Bout duration
(min) Bouts
Total duration
(min)
1 100 1.00 10 3 30
2 100 1.00 15 2 30
3 100 1.00 15 3 45
4 100 1.00 30 1 30
5 100 1.00 30 2 60
6 100 1.25 30 2 60
7 100 1.25 60 1 60
8 100 1.25 60 1 60
Figure 3 Participants actively performing arm cycle 
ergometry training (ACET) (A) and passive (assisted) body 
weight-supported treadmill training (BWSTT) (B). The 
participant and staff members (AAA and TEN) in panels A 
and panel B, respectively, provided consent to publish these 
images.
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will be recorded over 24 hours outside the laboratory 
(Meditech ABPM-04, Budapest, Hungary) for participants 
at the Vancouver site only. BP will be measured at 30 min 
intervals between 06:00 and 09:00, at 15 min intervals 
between 09:00 and 21:00, and every hour between 21:00 
and 06:00. Severity of AD, OH and subjective symptoms 
Table 3 Summary of assessments at each time period
Study period
Enrolment Allocation Post allocation (Tmonths)
Time point Tbaseline 0 T3 T6 T12
Enrolment
Eligibility screen X
Informed consent X
Familiarisation sessions X
Allocation X
Interventions:
• ACET 
• BWSTT 
Assessments:
primary outcome:
Arterial stiffness X X X
Secondary outcomes:
1. Cardiovascular parameters
  1.1 Left ventricular function structure* X X X
  1.2 Orthostatic instability X X
  1.3 Blood pressure lability* X X
2. Autonomic function
  2.1 Sympathetic skin response† X
  2.2 International autonomic standards 
evaluation†
X X
3. Blood sample
  3.1 Haematological profile and 
cardiovascular disease risk biomarkers
X X
4. Body composition
  4.1 Fat free mass and fat mass X X
  4.2 Waist and hip circumference X X
  4.3 Body mass index X X
5. Cardiorespiratory fitness
  5.1 Peak oxygen uptake X X
  5.2 Pain scale X X
  5.3 PANAS X X
6. Quality of life
  6.1 MOS SF-36 pain and general health X X X X
  6.2 Satisfaction with life scale X X X X
  6.3 Life satisfaction questionnaire X X X X
  6.4 Self-care, mobility, respiratory and 
sphincter management
X X X X
  6.5 Self-efficacy for aerobic exercise X X X X
  6.6 Impact on participation and 
autonomy questionnaire
X X X X
  6.7 Leisure time physical activity X X X X
*Data only collected at the Vancouver site.
†Data only collected at the Vancouver and Hamilton sites.
ACET, arm cycle ergometry training; BWSTT, body weight-supported treadmill training; MOS SF-36, medical outcome survey short form-36; 
PANAS, positive and negative affect scale
 o
n
 20 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-023540 on 4 January 2019. Downloaded from 
9Krassioukov AV, et al. BMJ Open 2019;9:e023540. doi:10.1136/bmjopen-2018-023540
Open access
(eg, light-headedness and dizziness) will also be assessed 
using a validated autonomic questionnaire.
Autonomic function
Sympathetic skin responses (SSRs)
The qualitative interpenetration of SSRs has been shown 
to be a reliable measure for assessing sudomotor function 
in persons with SCI56 and will be assessed at baseline for 
participants at the Vancouver and Hamilton sites. The 
response will be elicited by applying a square wave elec-
trical stimulation of 0.2 ms in duration to the median and 
tibial nerves and recorded bilaterally and simultaneously 
from both hands and feet to assess the extent of disrup-
tion to spinal autonomic pathways.57 Ten electrical stimuli, 
at an intensity sufficient to evoke a motor twitch (5–100 
mA), will be applied in a random order, with variable 
and long-time delays to minimise habituation. Amplitude 
and latency of the SSR will also be measured. Data will 
be recorded using the analog-to-digital converter Dantec 
Keypoint® 4 system (Natus Medical Incorporated, San 
Carlos, CA, USA). 
International autonomic standards evaluation
Until recently, individuals with SCI were only examined 
with the use of motor and sensory neurological standards 
in order to establish the level and severity of neurological 
impairment using the American Spinal Injury Associa-
tion Impairment Scale (AIS).58 During the last decade, 
international autonomic standards for the evaluation of 
SCI individuals were developed and implemented.59 This 
evaluation collects descriptive categorical data on cardio-
vascular (AD and OH) and other autonomic dysfunctions 
including bladder, bowel and sexual functioning.
Blood haematological profile and cardiovascular disease risk 
biomarkers
Certified clinical laboratories at each site will analyse all 
blood samples. Following a 12-hour overnight fast, including 
no food or drink (water is permitted), alcohol or caffeine, 
a trained technician will draw a venous blood sample. 
Complete blood cell count and biomarkers of cardiovas-
cular disease risk will be assessed at baseline and follow-up 
using various analytical techniques outlined in table 4.
Body composition
Visceral adipose tissue (VAT) is closely associated with 
cardiometabolic disease; VAT is vascularised, more meta-
bolically active and negatively impacts an individual’s 
metabolic profile leading to glucose intolerance, insulin 
resistance and hyperlipidaemia.60 Dual-energy X-ray 
absorptiometry (DXA) has been shown as a valid and 
reliable measure of abdominal adiposity when compared 
with CT and MRI.61 Furthermore, whole body DXA scans 
have been shown to have high levels of precision when 
performed on individuals with SCI.62
Whole body scans will be acquired using the Hologic 
4500 A or W densitometer (Waltham, Massachusetts, 
USA) and analysed centrally using commercially avail-
able Hologic software (V.13.4.1:5 Auto Whole Body). 
Routine densitometer and quality control checks will be 
completed daily and weekly as indicated by the manufac-
turer. Outcomes will be reported according to Interna-
tional Society for Clinical Densitometry guidelines63 and 
include whole body fat (kg), lean soft tissue mass (kg), 
percentage body fat, fat mass index (kg/m2), trunk/
limb fat mass ratio, android/gynoid ratio, trunk fat 
mass (kg), percentage trunk fat, VAT (cm2), lean soft 
tissue mass index (kg/m2) and appendicular lean mass 
index (kg/m2). Scans will be excluded from full analysis 
if a movement artefact is evident in any limb; only VAT 
outcomes will be included. If a limb is outside of the scan 
limit boarder, values from the contralateral side will be 
replicated. Height (length) will be measured using the 
electronic ruler function of the DXA plinth. Waist circum-
ference will be measured in the supine position following 
a normal expiration to the nearest 1 cm midway between 
the lowest lateral border of the ribs and the uppermost 
Table 4 Blood haematological and metabolic profiles
Haematological profile
CBC (white blood cells and differentials, erythrocytes, packed 
cell volume, haematocrit, platelets, haemoglobin and red cell 
indices).
Analytical techniques
Automated haematology system (Sysmex XE-2100TM, 
Sysmex, Mississauga, Ontario, L4W 4Y4, Canada)
CVD risk biomarkers
Lipid profile (triglycerides, TC, LDL-C, HDL-C, TC/HDL-C) and 
blood glucose.
Analytical techniques
Measured in plasma using an automated analyser (Cobas 
8000, C701, Roche Diagnostics, Rotkreuz, Switzerland), in 
accordance with manufacturer’s instructions via commercially 
available immunoassays (Roche Diagnostics, Rotkreuz, 
Switzerland).
Glycated haemoglobin (HbA1c). Measured in whole blood using an automated analyser (Roche 
Cobas c513, Roche Diagnostics, Rotkreuz, Switzerland), 
in accordance with manufacturer’s instructions via a 
commercially available immunoassay (Tina-quant HbA1c Gen. 
3).
CBC, complete blood count; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; TC, total cholesterol.
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lateral iliac crest. Waist circumference is considered the 
most practical surrogate for VAT in individuals with SCI 
and is tightly associated with cardiometabolic disease 
biomarkers.24
Cardiorespiratory fitness
Aerobic and anaerobic parameters will be assessed 
using a graded exercise test on an electrically braked 
arm-crank ergometer (Lode BV, Groningen, The Neth-
erlands; Vancouver site, Monark 881E, Monark Exercise 
AB, Vansbro, Sweden; Toronto and Hamilton sites). HR 
will be monitored continuously using a chest strap HR 
monitor (T31; Polar Electro, Woodbury, New York, USA), 
while expired gas will be measured using a metabolic 
cart (Parvomedics Truemax 2400, Sandy, Utah, USA; 
Vancouver site: Vmax Encore, SensorMedics, California, 
USA; Toronto site: Moxus Metabolic System, AEI Tech-
nologies, Illinois, USA; Hamilton site). The test will begin 
with 2 min of resting measures including HR, cardiore-
spiratory variables and BP (Dinamap Carescape V100; 
GE Healthcare, Buckinghamshire, UK). Following this, 
participants will be instructed to cycle at 50 rpm for 2 min 
with a resistance of 0 watts as a warm-up. The test itself 
will last approximately 6–15 min depending on the partic-
ipants’ fitness level.64 Workload will be increased every 
minute by 10 watts until volitional fatigue or the cadence 
drops below 30 rpm. A 2 min cool-down period will be 
provided at the end of the test. RPE will be assessed at the 
end of every minute using the 6–20 Borg scale, with the 
aim for each participant to achieve a value indicative of 
maximal effort (≥17). Peak oxygen uptake (VO2peak) will 
be taken as the highest 20 s average value collected from 
breath-by-breath gas exchange measurements during the 
test. Changes in submaximal exercise capacity parameters 
(ie, oxygen uptake at ventilatory threshold) will also be 
identified using different methods.65
Quality of life and physical activity outcomes
Several questionnaires (discussed below) will be admin-
istered over the telephone pre (0 months), during (3 
months) and post-exercise (6 months) intervention and 
at follow-up (12 months, unless otherwise stated). All 
participants will be contacted by KMG.
Quality of life
Pain and general health will be assessed using subscales 
from the medical outcomes survey short form-36.66 
Musculoskeletal pain will also be assessed using an 
11-point visual analogue scale ranging from 0 (no pain) 
to 10 (unbearable pain). The positive and negative affect 
scale (PANAS)67 will also be completed. Participants will 
be asked to rate the extent to which they experience 10 
negative (distressed, upset, guilty, ashamed, hostile, irri-
table, nervous, jittery, scared and afraid) and 10 positive 
(interested, alert, attentive, excited, enthusiastic, inspired, 
proud, determined, strong and active) emotions on a 
5-point Likert scale ranging from ‘very slightly’ to ‘very 
much’. Together these are generally regarded to be valid 
and reliable items for assessing the impact of changes in 
functional status on psychological well-being.68 The visual 
analogue pain scale and the PANAS will be administered 
pre-VO2peak and post-VO2peak testing. Life satisfaction will 
be assessed using the five-item satisfaction with life scale69 
and nine-item life satisfaction questionnaire.70 Validity 
for both life satisfaction measures has previously been 
confirmed in individuals with SCI.71 To ascertain changes 
in self-care, mobility, respiratory and sphincter manage-
ment, the spinal cord independence measure (SCIM III), 
which has been shown to be more sensitive to changes 
in function than the functional independence measure,72 
will also be administered.
Habitual physical activity level and exercise perceptions
Self-efficacy to engage in moderate and heavy aerobic 
exercise will be measured, asking participants to rate how 
confident (1=not at all confident, 7=completely confi-
dent) they are that they can perform: (A) moderate inten-
sity and (B) heavy-intensity activity, without stopping, for 
10 min, 20 min, 30 min, 40 min, 45 min and 60 min. Items 
from the impact on participation and autonomy ques-
tionnaire will also be completed to determine changes 
in participants’ indoor and outdoor autonomy and social 
relations (in the context of their disability). Lastly, the 
leisure-time physical activity questionnaire for people 
with SCI will be administered to determine changes in 
the performance of mild, moderate and heavy-intensity 
leisure-time physical activity. This brief questionnaire was 
designed specifically for individuals with SCI, with prelim-
inary evidence showing acceptable criterion validity and 
reliability.73
data management
All collected data (electronic or hardcopy documents) 
will be coded with unique identification numbers and 
stored centrally on the Empower database, a pass-
word-protected computer or in a locked filing cabinet 
in a secure laboratory space, only accessible to the study 
investigators. Data transfer between each study site will be 
encrypted to ensure participant identity is protected from 
unauthorised parties. All data will be stored for 25 years 
after publication, after which it will be destroyed.
statistical analysis
Linear mixed effects models, which provide a flexible 
framework for the analysis of longitudinal data, with 
the capability of estimating variance heterogeneity and 
within-participant residual correlations (ie, correlations 
among repeated within-subject measurements) will be 
used. The primary fixed effects for the model will be 
time, parameterised as either a 2-level or 3-level factor 
(baseline, 3 months of training and 6 months of training) 
(depending on the specific outcome measure); exercise 
group, parameterised as a two-level factor (ACET and 
BWSTT); and a time×exercise group interaction. Study 
site will be included as a fixed-effect control factor, and the 
mixed effects model will be suitably flexible to permit the 
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inclusion of additional controlling covariates, such as sex 
or time since injury. The model intercept term will also be 
included as random effects per participant in the model. 
From the mixed effects model, we will generate point and 
interval estimates of cfPWV at each of the study evaluation 
time points for both intervention groups. The evaluation 
of the objectives will be via appropriate linear contrasts 
applied to the linear mixed effects model to contrast 
3-month and 6-month changes in cfPWV and compare 
postintervention cfPWV between exercise groups. The 
linear contrasts for the evaluation of the objective are 
comparable with two-sample t-tests, and the mixed effects 
model, and associated contrasts, require random effects 
and residual normality. Should these assumptions fail, 
we will apply the non-parametric Wilcoxon rank sum 
test (stratified by study site) to compare 3-month and 
6-month changes in cfPWV between exercise groups. All 
comparisons will be conducted at the 0.05 significance 
level. The trial statistician will be blinded to participant’s 
group allocation. An intention-to-treat analysis will be 
performed taking into consideration participants that 
were withdrawn from the trial.
Power calculation and sample size
Assuming a sample size of 30 participants per exer-
cise intervention group, a significance level of 0.05 and 
that the SD of cfPWV will be 10% of the baseline value 
(SD=1.3), these contrasts will have 80% power to detect 
exercise group differences of ≥1.0 m/s. Our target effect 
size of 1 m/s is in line with reported effects of exercise 
interventions in other high-risk populations, such as 
sedentary, postmenopausal women and individuals with 
hypertension; in these studies, 1–3 months of endurance 
exercise training was associated with reductions in cfPWV 
of 0.8 m/s74 and 1 m/s.75 Additionally, 1 m/s is a clini-
cally meaningful improvement, as each 1 m/s increase 
in cfPWV, translates into a 15% increased risk of CV 
mortality.16
safety
A Data and Safety Monitoring Committee will be composed 
of four individuals external and independent to the study 
to review adverse event (AE) reports, which will intervene 
and insist the study is terminated prematurely should 
the AE data be of sufficient concern. Any AEs reported 
during training will be documented with information 
pertaining to their severity and anatomical location. Any 
serious AEs will be immediately reported to the Data and 
Safety Monitoring Committee, as well as to the appro-
priate ethics boards at each site by the study coordinator.
Ethics and dissemination
Any protocol modifications will be clearly communi-
cated to the sponsor and ethics committee. This trial 
will be conducted in full compliance with Good Clinical 
Practice, with all researchers involved having completed 
the Tri-Council Policy Statement: Ethical Conduct for 
Research Involving Humans Course on Research Ethics. 
The results of the CHOICES trial will be presented 
at national and international conferences and will be 
published in peer-reviewed journals. Any subsequent 
outcome manuscripts will be reported in conjunction 
with the Consolidated Standards of Reporting Trials.76 
Additionally, a summary of the study’s findings will be 
posted on the ICORD website and published in the maga-
zines of service organisations for people with SCI in the 
provinces where participants were recruited (ie, the SCI 
BC and SCI ON magazine publications). Extensive, indi-
vidualised feedback will be provided to each study partic-
ipant once they have completed the trial.
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